Meeting
2018 ASCO Annual Meeting
Impact of cholangiocarcinoma (CC) molecular heterogeneity on outcome during first-line chemotherapy and access to targeted therapies in early clinical trials (CT).
Authors
Helena Verdaguer
Vall d’Hebron University Hospital, Barcelona, Spain
Helena Verdaguer , Irene Brana , Cinta Hierro , Analia Azaro , Elena Elez , Elena Garralda , Berta Laquente , Juan Francisco Grau Bejar , Fiorella Ruiz-Pace , Cristina Viaplana , Susana Aguilar , Rodrigo Dienstmann , Teresa Macarulla Mercade
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4091)
DOI
10.1200/JCO.2018.36.15_suppl.4091
Abstract #
4091
Poster Bd #
280
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2022 ASCO Annual Meeting
Evaluation of stage IV pancreatic adenocarcinomas based on mutational profiling of tumors.
First Author: Katherine E Poruk